{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:52:08Z","timestamp":1779223928981,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":332,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pharmacological and Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Due to its resistance to common anti\u2010TB drugs, multidrug\u2010resistant tuberculosis (MDR\u2010TB) presents substantial treatment problems. Optimizing therapeutic outcomes requires individualized treatment plans that take into account patient comorbidities, medication susceptibility profiles, and past treatment history. The significance of individualized medication in the treatment of MDR\u2010TB is emphasized in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods of Review<\/jats:title>\n                    <jats:p>Current research on tailored treatment plans for MDR\u2010TB is summarized in this review. It highlights how pharmacogenomics, medication sensitivity testing, and patient\u2010centered care can be used to customize treatment plans. The utilization of combination therapies, monitoring and adaptation techniques, and novel treatment options\u2014such as adjuvant therapy and newer agents\u2014are also covered in the review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Important findings show that thorough medication susceptibility testing is essential for directing wise treatment decisions. Dosage modifications based on individual metabolic responses can be informed by pharmacogenomic data. Treatment regimen adherence is improved when patients participate in decision\u2010making. Combination therapy involving new drugs has demonstrated potential for increasing therapeutic effectiveness while reducing the emergence of resistance. Frequent monitoring makes it possible to promptly modify therapy in response to the patient response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment for MDR\u2010TB must be individualized and comprehensive due to its complexity. For individuals with MDR\u2010TB, therapy outcomes can be greatly enhanced while lowering the risk of further resistance by combining host\u2010directed therapies, pharmacological breakthroughs, and continuous patient monitoring. Enhancing customized care solutions in this difficult field of infectious illness management requires ongoing research and innovation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/adpp\/8849786","type":"journal-article","created":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T04:04:55Z","timestamp":1764475495000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel Pharmacological Approaches for Multidrug\u2010Resistant Tuberculosis: Review"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7262-8663","authenticated-orcid":false,"given":"Kassahun Dires","family":"Ayenew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habtemariam Alekaw","family":"Habteweld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abate Wondesen","family":"Tsige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3606-9803","authenticated-orcid":false,"given":"Yihenew Sewale","family":"Bizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"e_1_2_15_1_2","volume-title":"Global Tuberculosis Report 2021","author":"WHO","year":"2021"},{"key":"e_1_2_15_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S457308"},{"key":"e_1_2_15_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13040722"},{"key":"e_1_2_15_4_2","doi-asserted-by":"publisher","DOI":"10.70070\/qnnnjb97"},{"key":"e_1_2_15_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612819666131118164434"},{"key":"e_1_2_15_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fddsv.2023.1254656"},{"key":"e_1_2_15_7_2","first-page":"2125","article-title":"Substantial Reduction in Mortality With Bedaquiline-Containing Regimens for Drug-Resistant Tuberculosis","volume":"374","author":"Dorman S. E.","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_15_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112433"},{"key":"e_1_2_15_9_2","first-page":"1031","article-title":"Inhalable Drug Formulations for Tuberculosis Treatment","volume":"16","author":"Mason C.","year":"2019","journal-title":"Expert Opinion on Drug Delivery"},{"key":"e_1_2_15_10_2","article-title":"Immunomodulation Strategies Against Mycobacterium tuberculosis","volume":"8","author":"Zhang L.","year":"2017","journal-title":"Frontiers in Microbiology"},{"key":"e_1_2_15_11_2","first-page":"519","article-title":"Pharmacogenomics of Tuberculosis Treatments","volume":"20","author":"Meyer E.","year":"2020","journal-title":"The Pharmacogenomics Journal"},{"key":"e_1_2_15_12_2","volume-title":"Old and New TB Drugs: Mechanisms of Action and Resistance","author":"Anastasia S.","year":"2012"},{"key":"e_1_2_15_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.13934"},{"key":"e_1_2_15_14_2","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10085-8101"},{"key":"e_1_2_15_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1313865"},{"key":"e_1_2_15_16_2","unstructured":"U.S. Food and Drug Administration (FDA) Bedaquiline: 2019; Drug Label."},{"key":"e_1_2_15_17_2","volume-title":"Guidelines for the Treatment of drug-susceptible Tuberculosis and Patient Care","author":"World Health Organization (WHO)","year":"2019"},{"key":"e_1_2_15_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"key":"e_1_2_15_19_2","first-page":"2400","article-title":"Nix-TB: a Phase 3 Trial of a Novel Treatment for Multidrug-Resistant Tuberculosis","volume":"380","author":"Rustomjee R.","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_15_20_2","volume-title":"Labeling for Pretomanid","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"e_1_2_15_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.973853"},{"key":"e_1_2_15_22_2","doi-asserted-by":"publisher","DOI":"10.4103\/0255-0857.99481"},{"key":"e_1_2_15_23_2","doi-asserted-by":"crossref","unstructured":"RskS. VM. MD.et al. OvercomingMycobacterium tuberculosisDrug Resistance: Novel Medications and Repositioning Strategies 2023 https:\/\/doi.org\/10.1021\/acsomega.3c02563.","DOI":"10.1021\/acsomega.3c02563"},{"key":"e_1_2_15_24_2","volume-title":"The End TB Strategy: Global Strategy and Targets for Tuberculosis Prevention, Care and Control After","author":"World Health Organization","year":"2015"},{"key":"e_1_2_15_25_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmy.ijmy_75_20"},{"key":"e_1_2_15_26_2","first-page":"1","article-title":"A Novel Approach for the Treatment of Multidrug-Resistant Tuberculosis: a Case Report","volume":"21","author":"Matsumoto S.","year":"2021","journal-title":"BMC Infectious Diseases"},{"key":"e_1_2_15_27_2","doi-asserted-by":"publisher","DOI":"10.21776\/ub.pji.2023.008.02.10"},{"key":"e_1_2_15_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.36"},{"key":"e_1_2_15_29_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4644"},{"key":"e_1_2_15_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/35100531"},{"key":"e_1_2_15_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ115"},{"key":"e_1_2_15_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom14121497"},{"key":"e_1_2_15_33_2","doi-asserted-by":"publisher","DOI":"10.7175\/rhc.v3i1.67"},{"key":"e_1_2_15_34_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.18.0622"},{"key":"e_1_2_15_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121397"},{"key":"e_1_2_15_36_2","article-title":"Cost-Effectiveness of New Tuberculosis Treatments: a Systematic Review","volume":"14","author":"Vassall A.","year":"2017","journal-title":"PLoS Medicine"}],"container-title":["Advances in Pharmacological and Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/adpp\/8849786","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/adpp\/8849786","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/adpp\/8849786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T21:23:29Z","timestamp":1773005009000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/adpp\/8849786"}},"subtitle":[],"editor":[{"given":"Koteshwara","family":"Mudigonda","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/adpp\/8849786"],"URL":"https:\/\/doi.org\/10.1155\/adpp\/8849786","archive":["Portico"],"relation":{},"ISSN":["2633-4682","2633-4690"],"issn-type":[{"value":"2633-4682","type":"print"},{"value":"2633-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2025-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"8849786"}}